Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley

1 hour ago 1

TipRanks

Thu, January 1, 2026 astatine 7:25 AM CST 1 min read

B. Riley raised the firm’s price target connected Vanda Pharmaceuticals (VNDA) to $14 from $11 and keeps a Buy standing connected the shares aft the FDA approved Nereus for prevention of vomiting induced by question sickness. The quality supports the presumption that Vanda is an “ongoing turnaround story” trading astatine an “excessive discount” heading into 2 much imaginable approvals wrong the adjacent 12 months, the expert tells investors successful a probe note. Riley says that portion the support could unlock implicit $100M successful highest revenue, the greater value is successful the implications for tradipitant support successful GLP-1 related nausea.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected VNDA:

Disclaimer & DisclosureReport an Issue

Vanda question sickness support comes with ‘broad’ label, says Cantor
Vanda Wins FDA Approval for NEREUS Motion Sickness Drug
Vanda jumps 18% to $8.33 aft question sickness FDA approval
Vanda receives FDA support of Nereus for question sickness
Vanda Pharmaceuticals terms people raised to $7.50 from $5 astatine Jefferies

Read Entire Article